NICE says final no to Roche's Avastin in metastatic breast cancer
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has published final guidance rejecting Roche's VEGF targeted anticancer Avastin (bevacizumab) for metastatic breast cancer because of doubts over the drug's effectiveness coupled with its high cost.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.